Sarepta Therapeutics, Inc. et al. vs. Genzyme Corporation et al.

Explore the PTAB proceeding IPR2026-00168 filed by Sarepta Therapeutics, Inc. et al. on 2025-12-02. This includes filing dates, application numbers, tech centers, patent numbers, and current case status.

Proceeding Overview

Proceeding Number

IPR2026-00168

Filing Date

2025-12-02

Accorded Filing Date

2025-12-02

Institution Decision Date

2026-05-15

Last Modified Date

2026-07-28

Proceeding Type

IPR

Termination Date

2026-05-15

Trial Status

Institution Denied

Parties & Counsel

Petitioner

Sarepta Therapeutics, Inc. et al.

Represented By

Wilson, Robertet al

Patent Owner / Respondent

Genzyme Corporation et al.

Represented By

Antons, Amandaet al

Tribunal & Venue

Tribunal

Patent Trial and Appeal Board (USPTO)

Technology Center

TC 1700 - Chemical & Materials Engineering

Patent Information

1 Patent Involved

Respondent Application Number 18321542

Respondent Patent Number 12123880

External Links

Espacenet

Google Patents

Respondent Inventor Xiaoying JIN et al

Respondent Tech Center TC 1700 - Chemical & Materials Engineering

Address and Attorney/Agent Information

40 Registered Practitioners

Power of Attorney & Correspondence

Firm / Entity Name Sanofi/Genzyme c/o Morrison & Foerster LLP

Customer Number 89300

Address 755 Page Mill Road, Palo Alto, CA, 94304, UNITED STATES

Attorney / Agent Information

Reg #	Name	Phone
36844	Joseph Kirk Jr	908-981-6911
39150	John Conway	908-981-6688
40564	Anne Collins	978-341-0036
44045	Sandra Brockman-Lee	857-523-9199
45736	Pamela Torpey	508--27-1-0683
45979	Milan Vinnola	619-238-0062
47150	Nicole Parsons	617-685-5697
52610	Kelly Bender	2485930581
54154	Allyson Hatton	508-361-7392
54958	Janann Ali	617-685-5645
58163	Alejandro Martinez	617-685-5935
59682	Jeremy Bond	617-685-5653
61358	Ryan Mcquade	617-838-5595
61393	Isaac Hubner	617-866-4544
62108	Siew Chong	973-980-0397
63001	Stephanie Donahue	908-331-4406
63750	Mayssam Ali	617-685-5646
64259	Xuemei Peng	908-981-6951
64740	Alan Townsley	202-857-2278
64828	Jeffrey Weber	617-685-6431
66863	Patricia Callanan	617-866-4404
67265	Yi Wang	617-685-5735
67340	Dhruv Kaushal	617-245-4065
68308	Jonathan Andron	617-685-5658
68315	Meenakshy Chakravorty	781-418-9211
69032	Robert Bolcome Iii	857-331-1597
69052	Jing Wang	617-951-8720
69953	Janet Tse	617-564-6571
70740	Erika Wallace	617-937-1397
71226	Meghan Klaric	313-465-7211
72110	Daniel Tate	800-981-2491
72475	Indrani Dasgupta	617-685-5977
72868	David Lefebvre	617-685-5338
72919	Ted Ririe	385-312-6536
74124	Evan King	781-234-4286
75427	Shirley Tan	617-646-8444
77001	Sara Haines	003-348-1492783
80264	Christopher Marion	314-517-7022
80424	Victoria Pedanou	508-736-4409
81386	Erin May	617-251-9709

Proceeding Documents

110

Notice of Refund NOTICE

2026-07-28 FILING PARTY: BOARD

Download

Refund Request OTHER

2026-07-16 FILING PARTY: PETITIONER

Download

Institution Decision: Deny DECISION

2026-05-15 FILING PARTY: BOARD

Download

Director Discretionary Decision: Refer RESPONSE

2026-03-23 FILING PARTY: BOARD

Download

1048

Ex. 1048 Exhibit

2026-03-04 FILING PARTY: PETITIONER

Download

Sarepta Therapeutics, Inc. et al. vs. Genzyme Corporation et al.

Proceeding Overview

Parties & Counsel

Petitioner

Sarepta Therapeutics, Inc. et al.

Represented By

Patent Owner / Respondent

Genzyme Corporation et al.

Represented By

Tribunal & Venue

Patent Information

Address and Attorney/Agent Information

Power of Attorney & Correspondence

Attorney / Agent Information

Proceeding Documents

Notice of Refund NOTICE

Refund Request OTHER

Institution Decision: Deny DECISION

Director Discretionary Decision: Refer RESPONSE

Ex. 1048 Exhibit

Ex. 1054 Exhibit

Ex. 1058 Exhibit

Ex. 1051 Exhibit

Ex. 1052 Exhibit

Ex. 1045 Exhibit

Ex. 1056 Exhibit

Ex. 1044 Exhibit

Ex. 1055 Exhibit

Ex. 1046 Exhibit

Ex. 1053 Exhibit

Ex. 1049 Exhibit

Ex. 1057 Exhibit

Ex. 1050 Exhibit

Ex. 1043 Exhibit

Ex. 1041 Exhibit

Response to Patent Owner's Discretionary Denial Brief RESPONSE

Ex. 1042 Exhibit

May & McLean, “Advanced Multidimensional Separations in Mass Spectrometry: Navigating the Big Data Deluge,” Exhibit

Kontogiannis et al., “Characterization of AAV vectors: A review of analytical techniques and critical quality attributes,” Exhibit

ICH Harmonised Tripartite Guideline: Validation of Analytical Procedures: Text and Methodology Q2(R1) Exhibit

Lancaster and Ha et al., “Characterization of N-glycosylation profiles from mammalian and insect derived chikungunya VLP,” Exhibit

Patent Owner's Preliminary Response POPR

Curriculum Vitae of John A. McLean, Ph.D. Exhibit

Han, Aslanian, & Yates, “Mass spectrometry for proteomics,” Exhibit

Wörner and Heck et al., “Adeno-associated virus capsid assembly is divergent and stochastic,” Exhibit

Declaration of John A. McLean, Ph.D. Exhibit

Valeja et al., “Three Dimensional Liquid Chromatography Coupling IEC/HIC/RPC for Effective Protein Separation in Top-Down Proteomics,” Exhibit

Boys et al., “Protein Oxidative Modifications During Electrospray Ionization: Solution Phase Electrochemistry or Corona Discharge-Induced Radical Attack?,” Exhibit

Knolhoff, Callahan, and Croley, “Mass Accuracy and Isotopic Abundance Measurements for HR-MS Instrumentation: Capabilities for Non-Targeted Analyses,” Exhibit

Supplemental Materials to Ansong et al., “Top-down proteomics reveals a unique protein S-thiolation switch in Salmonella Typhimurium in response to infection-like conditions,” Exhibit

Wright & Wright, “Advances in LC: Bioanalytical Method Transfer,” Exhibit

Salganik et al., “Evidence for pH-Dependent Protease Activity in the Adeno-Associated Virus Capsid,” Exhibit

Ex. 1047 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 92 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 35 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 91 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 102 Exhibit

US Patent 11,698,377 File History Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 28 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 99 Exhibit

Patent Owner's Request for Discretionary Denial RESPONSE

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) - Defendant’s Supplemental Initial Invalidity Contentions Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 45 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. Joint Claim Construction Chart Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 67 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 37 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 59 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 87 Exhibit

US Patent 11,698,377 Exhibit

Bark Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 76 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 78 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 68 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 83 Exhibit

Genzyme Corporation v. Sarepta Therapeutics Inc. (1:24-cv-00882) D.I. 110 Exhibit

Vliet Exhibit

Patent Owner's Updated Mandatory Notices NOTICE

Petitioner's Sotera Stipulation OTHER

Declaration of Katherine Helm Exhibit

Notice of Intent to Designate Katherine Helm as Back-Up Counsel NOTICE